



# Aposave Clinical Trial Comparator Survey


Global Clinical Supplies Group

September, 2020




- ❖ Respondents accessed this survey via the Aposave virtual booth at the GCSG 2020 conference
- ❖ All surveys were completed between 21<sup>st</sup> and 25<sup>th</sup> September 2020
- ❖ A total of 40 surveys were completed
- ❖ 23 pharmaceutical and biotechnology companies were represented

# Q1: What are the top 3 challenges you face when sourcing comparator drugs?




## Q2: Of the below options, what is the most important to reduce the risks associated with comparative trials?



Q3: To what extent do each of the comparator elements impact the broader study? (1 = lowest; 4 = highest)




### 3a) Compliance Challenges



Q3: To what extent do each of the comparator elements impact the broader study? (1 = lowest; 4 = highest)


### 3b) Supply to individual sites



Q3: To what extent do each of the comparator elements impact the broader study? (1 = lowest; 4 = highest)




### 3c) Packaging



Q3: To what extent do each of the comparator elements impact the broader study? (1 = lowest; 4 = highest)




### 3d) Wastage







# Q4: What are the top 3 factors that you consider when deciding to partner with a 3rd party?



Q5: Has patient recruitment and retention been negatively impacted in any of your clinical trials due to COVID-19 disruptions?



Q6: Do you believe that any of your clinical trial comparator inventory is at risk of write-off due to COVID-19 disruptions?





A new approach to  
Clinical Trial Solutions,  
maximizing efficiency  
and minimizing costs



Ian Hoban  
Business Development Director  
Clinical Trial Solutions

Email: [ian.hoban@aposave.com](mailto:ian.hoban@aposave.com)  
[www.aposave.com](http://www.aposave.com)

